Peripheral Leukocytosis Predicts Cognitive Decline but Not Behavioral Disturbances: A Nationwide Study of Alzheimer’s and Parkinson’s Disease Patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Peripheral Leukocytosis Predicts Cognitive Decline but Not Behavioral Disturbances: A Nationwide Study of Alzheimer’s and Parkinson’s Disease Patients ; volume:50 ; number:2 ; year:2021 ; pages:143-152 ; extent:10
Dementia and geriatric cognitive disorders ; 50, Heft 2 (2021), 143-152 (gesamt 10)
- Urheber
-
Unda, Santiago R.
Antoniazzi, Aldana M.
Altschul, David J.
Marongiu, Roberta
- DOI
-
10.1159/000516340
- URN
-
urn:nbn:de:101:1-2021090200184766400783
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Unda, Santiago R.
- Antoniazzi, Aldana M.
- Altschul, David J.
- Marongiu, Roberta
Ähnliche Objekte (12)
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
The aging immune system in Alzheimer’s and Parkinson’s diseases
Alzheimer, Parkinson und andere Alterskrankheiten
Comparing Alzheimer’s and Parkinson’s diseases networks using graph communities structure
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Circulatory miR-223-3p Discriminates Between Parkinson’s and Alzheimer’s Patients
Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
Impaired 24-h activity patterns are associated with an increased risk of Alzheimer’s disease, Parkinson’s disease, and cognitive decline
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
The aging immune system in Alzheimer’s and Parkinson’s diseases
Alzheimer, Parkinson und andere Alterskrankheiten
Comparing Alzheimer’s and Parkinson’s diseases networks using graph communities structure
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Circulatory miR-223-3p Discriminates Between Parkinson’s and Alzheimer’s Patients
Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
Impaired 24-h activity patterns are associated with an increased risk of Alzheimer’s disease, Parkinson’s disease, and cognitive decline
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
The aging immune system in Alzheimer’s and Parkinson’s diseases
Alzheimer, Parkinson und andere Alterskrankheiten
Comparing Alzheimer’s and Parkinson’s diseases networks using graph communities structure
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Circulatory miR-223-3p Discriminates Between Parkinson’s and Alzheimer’s Patients
Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease